News
Novo Nordisk announces CEO transition as share price slips
After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight loss drugs.
CEO of Novo Nordisk, maker of Wegovy, is stepping down
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing “recent market challenges” and a steep decline in the company’s share price.
"We look forward to the opportunity to introduce this evidence again through the legal process and in discussions ... was based on a thorough review of Novo Nordisk's stable and growing supply ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Moreover, Novo Nordisk also claims that it is difficult to manufacture liraglutide and "even small changes in the manufacturing process of ... made a similar case for semaglutide in a petition ...
A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.
Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying patients. Semaglutide, the first weekly GLP-1 RA for weight management, now ...
Novo Nordisk (NVO ... through the legal process and in discussions with the FDA. Compounders and telehealth providers have continued their offerings for both Novo's semaglutide and Eli Lilly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback